SCHEMBL4395965

SCHEMBL4395965

CCOc1cc(OC)c(F)c(C#N)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.38
PDE4B Q07343 6/20 0.38
PDE4C Q08493 6/20 0.38
PDE4D Q08499 6/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 3/20 0.36
KDM4E B2RXH2 3/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.36
ENPP1 P22413 1/20 0.35
SRC P12931 1/20 0.35
MAPK1 P28482 2/20 0.35
TRPV4 Q9HBA0 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405119 0.94 PDE4A (0.38) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL4401362 0.87 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4401613 0.87 MAPT (0.37) NPC1RAB9AMAPTKDM4EKMT2A
SCHEMBL4399086 0.82 KDM4E (0.40) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL5398415 0.80 KDM4E (0.40) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4406875 0.78 KDM4E (0.42) MAPTKDM4EKMT2AALDH1A1RECQL
SCHEMBL4405384 0.76 ESR1 (0.38) NPC1RAB9AMAPTKDM4EKMT2A
SCHEMBL4543726 0.76 KDM4E (0.44) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL4408963 0.74 ENPP1 (0.36) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4406805 0.73 TRPV4 (0.37) PDE4APDE4BPDE4CPDE4DNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 PDE4A 1438/4885PDE4B 1642/4885PDE4C 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.